Table 2.
Progression to a higher Global-CDR
| Progression in CN participants | |||||
| Total N = 852 |
Stable N = 806 |
Converters N = 46 |
p | ||
| Median | Q1– Q3 | Median | Q1 – Q3 | ||
| Baseline age (years) | 66.0 | 61.0 – 71.0 | 73.0 | 70.0 – 79.0 | < .001 |
| Education (years) | 13.0 | 10.0 – 18.0 | 15.0 | 12.0 – 18.0 | .110 |
| Sex (% females/males) | 57/43% | 50/50% | .314 | ||
| APOE ε4 carriers (%Yes/No/Missing) | 37.8/61.8/0.4% | 39/61/0% | .992 | ||
| Baseline MMSE (/30) | 29.0 | 29.0 – 30.0 | 29.0 | 28.0 – 30.0 | .249 |
| FU duration (years) | 3.0 | 2.0 – 4.4 | 4.9 | 3.2 – 5.2 | < .001 |
| Number of visits | 3.0 | 2.0 – 3.75 | 5.0 | 3.0 – 6.0 | < .001 |
| Baseline CL | 5.6 | -1.1 – 16.3 | 12.9 | 2.5 – 42.1 | .007 |
| Baseline CL group (Aβ-/Aβ± /Aβ+) | 68/23/9% | 50/26/24% | .006 | ||
| Progression in Global-CDR = 0.5 participants | |||||
| Total N = 118 |
Non-demented at FU N = 85 |
Demented at FU N = 33 |
p | ||
| Median | Q1– Q3 | Median | Q1 – Q3 | ||
| Baseline age (years) | 72.0 | 67.0 – 76.0 | 76.0 | 68.0 – 79.0 | .044 |
| Education (years) | 15.0 | 13.0 – 17.0 | 13.0 | 12.0 – 16.3 | .006 |
| Sex (% females/males) | 44/56% | 58/42% | .244 | ||
| APOE ε4 carriers (%Yes/No/Missing) | 43/55/2% | 67/30/3% | .026 | ||
| Baseline MMSE (/30) | 29.0 | 27.0 – 30.0 | 26.0 | 25.0 – 27.0 | < .001 |
| FU duration (years) | 2.4 | 1.8 – 4.0 | 3.9 | 2.1 – 4.4 | .042 |
| Number of visits | 3.0 | 2.0 – 4.0 | 3.0 | 2.0 – 3.0 | .064 |
| Baseline CL | 9.80 | -1.0 – 51.9 | 66.4 | 30.8 – 91.6 | < .001 |
| Baseline CL group (Aβ-/Aβ± /Aβ+) | 52/22/26% | 15/21/64% | < .001 | ||
Conversion to MCI was defined as having a consistent Global-CDR = 0.5 on the two last visits. Conversion to dementia was defined as having a Global-CDR ≥ 1 by the end of the FU
CL Centiloid, FU follow-up